Objective: Delayed cerebral ischemia (DCI) greatly contributes to the high morbidity and mortality of aneurysmal subarachnoid hemorrhage (aSAH) patients. Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) was substantially raised in the basilar arterial wall of SAH rabbits. We attempted to ascertain the relationship between serum soluble LOX-1 (sLOX-1) levels and the occurrence of DCI after aSAH.
| INTRODUC TI ON
Aneurysmal subarachnoid hemorrhage (aSAH) is one of the commonest cerebrovascular diseases and is characterized by a high mortality (Etminan & Macdonald, 2017; Grimm, 2015; Serrone, Maekawa, Tjahjadi, & Hernesniemi, 2015) . After aSAH, cerebral vasospasm can induce the decreased cerebral blood flow, subsequently resulting in delayed cerebral ischemia (DCI), and finally leading to severe neurological deficit and even death (Burrell et al., 2016; Francoeur & Mayer, 2016; Geraghty & Testai, 2017 ). The accumulating evidence shows microvasculature, coagulation and fibrinolytic systems, cortical spreading depressions, and the immune system might participate in pathophysiological process of DCI (Bacigaluppi et al., 2015; Carr, Zuckerman, & Mocco, 2013; Foreman, 2016) . However, the actual pathogenesis of DCI still warrants to be explored.
Oxidized low-density lipoprotein (ox-LDL) and its receptor, lectin-like ox-LDL receptor-1 (LOX-1), is involved in the pathogenesis of atherosclerosis by mediating various reactions and processes (Aoyama, Fujiwara, Masaki, & Sawamura, 1999; Li & Mehta, 2000; Mehta, Chen, Hermonat, Romeo, & Novelli, 2006; Sawamura et al., 1997) . Ox-LDL, via binding to LOX-1, increases intracellular reactive oxygen species, leads to a reduction in nitric oxide availability and down-regulates endothelial nitric oxide synthase and initiates the inhibition of vasodilatation (Ma et al., (2006) ; Sakurai & Sawamura, 2003) . Ox-LDL and LOX-1 were increased in the basilar arterial wall of rabbits with SAH (Matsuda et al., 2014) . So, it is assumed that LOX-1 might be implicated the pathogenesis of DCI. Soluble LOX-1 (sLOX-1) is generated through proteolytic cleavage of the extracellular domain of LOX-1 and, therefore, sLOX-1 can be utilized to distinguish acute coronary syndrome, acute spontaneous intracerebral hemorrhage, and acute ischemic stroke (Inoue et al., 2019; Misaka et al., 2014; Yokota et al., 2016) . However, sLOX-1 in the peripheral blood has not been explored in patients with aSAH. In this study, we intended to determine whether there is a difference in sLOX-1 levels between patients who incurred an aSAH and those who did not, and between patients who suffered from a DCI and those who did not.
We also investigated the usefulness of circulating sLOX-1 as an early predictor of DCI after aSAH.
| MATERIAL S AND ME THODS

| Study population
In this prospective observational study, we consecutively enrolled first-ever nontraumatic SAH patients who were admitted to the Department of Neurosurgery at our hospital within 24 hr of stroke onset from March 2015 to May 2019, and fulfilled the selection criteria as follows: (a) SAH caused by a single intracranial aneurysm confirmed via computerized tomography angiography or digital subtraction angiography, and (b) clipping or interventional treatment of the aneurysm was carried on within 48 hr after admission.
We also removed those patients with (a) any type of surgery or acute or chronic infection within recent a month; (b) previous other neurological diseases, for example, ischemic stroke, hemorrhagic stroke, and severe head trauma; (c) prior use of antiplatelet medication, anticoagulant drugs, or immunosuppressants; and (d) other systemic diseases such as autoimmune disease, uremia, cirrhosis, cancer, chronic lung diseases, and chronic heart diseases.
Additionally, a group of control individuals, free of other diseases, were recruited. This study was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and was also based on the ethical standards of our institution. This study was approved by the institutional ethics committees at our institution and the written informed consent was obtained from participants or their relatives.
| Patient management and clinical assessment
Treatment for aSAH was performed according to the guidelines from the American Heart Association and American Stroke Association (Connolly et al., 2012) . Critical care management was based on the guidelines from the Neurocritical Care Society (Diringer et al., 2011) . Hypertensive hypervolemic therapy was only done for patients with symptomatic vasospasm. We set target systolic blood pressure to 180-220 mmHg for poor-grade patients with severe angiographic vasospasm (Komotar et al., 2009) .
The modified Fisher grading scale was utilized to estimate the amount of subarachnoid blood presented on the head computerized tomography scan at admission. Clinical severity of aSAH was assessed on the basis of the initial Hunt and Hess scale, and World Federation of Neurosurgical Societies (WFNS) grade. In this study, admission WFNS grade, modified Fisher grade or Hunt-Hess grade ≥3, was identified as severe aSAH.We collected basic information (such as age and gender), aneurysmal morphological characteristics including shape, size and position, and other radiological parameters (such as acute hydrocephalus and intraventricular hemorrhage). Brain computerized tomography scans were carried out at days 1, 7, 14, and 30 following surgery. DCI was considered according to the criteria below: (a) clinical deterioration (namely, a new focal deficit, decrease in level of consciousness, or both), and/ or (b) a new infarct on head computerized tomography scan that was invisible at admission or immediately postoperatively and cannot be attributed to other causes by means of clinical assessment, imaging of the brain, and appropriate laboratory studies (Frontera et al., 2009 ).
| Measurements
Venous blood was drawn for patients at admission and for controls at study entrance. Blood samples were collected in sterile tubes, next centrifuged at 3,000 g for 15 min, aliquoted into 1.5-ml tubes and preserved at −80°C until analysis. sLOX-1 was detected with enzyme immunoassay, commercially available from NK Medico Co.
Ltd. Quantifications were completed in duplicate, and the results were averaged. Samples with obvious hemolysis were not utilized for further determinations. All measurements were completed in batches every 3 months by the same technician who was completely inaccessible to the clinical information. 
| Statistical analysis
| RE SULTS
| Subjects
All aSAH patients were screened during the enrollment period and eventually a total of 125 patients were analyzed. Simultaneously, 125 controls, with similar age and gender percentage, were chosen. Figure 1 shows that serum sLOX-1 levels were actually significantly higher in patients than in controls. In Figure 2 , serum sLOX-1 levels were highly correlated with admission WFNS, modified Fisher, and Hunt-Hess scores. In addition, patients with severe aSAH (WFNS scores, modified Fisher scores, or Hunt-Hess scores ≥ 3) exhibited significantly higher serum sLOX-1 levels than other remainders ( Figure 2 ).
| Serum sLOX-1 levels
| Serum sLOX-1 levels and DCI
In Figure 3 , serum sLOX-1 levels were substantially elevated in patients who presented with DCI, as compared with those who did not.
Furthermore, serum sLOX-1 levels were bifurcated based its median value (1,450.2 pg/ml). It was revealed that serum sLOX-1 levels >1,450.2 pg/ml and other variables listed in Table 1 , such as WFNS scores, modified Fisher scores, Hunt-Hess scores, external ventricular drainage, acute hydrocephalus, intraventricular hemorrhage, and F I G U R E 1 Difference of serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) levels between healthy controls and patients with aneurysmal subarachnoid hemorrhage blood glucose levels, were strongly associated with occurrence of DCI. Table 2 displayed their odds ratio and 95% confidence interval values. Moreover, we incorporated the preceding significant variables in the binary logistic regression model and thereby found that WFNS scores modified Fisher scores and serum sLOX-1 levels >1,450.2 pg/ml emerged as the independent predictors for occurrence of DCI (Table 3 ). Figure 3 shows that an optimal value of serum sLOX-1 levels (1617 pg/ml) was selected, which yielded the corresponding sensitivity and specificity values (Youden index = 0.569). Moreover, its predictive ability (AUC 0.825, 95% confidence interval (CI) 0.747-0.887) was equivalent to those of WFNS scores (AUC 0.867, 95% CI 0.795-0.921, p = .310) and modified Fisher scores (AUC 0.849, 95% CI 0.773-0.906, p = .589). Using a combined binary logistic regression model, serum sLOX-1 levels significantly improved AUCs of WFNS scores and modified Fisher scores to 0.903 (95% CI 0.838-0.949, p = .035) and 0.898 (95% CI 0.831-0.945, p = .028), respectively.
| D ISCUSS I ON
Delayed cerebral ischemia, a severe complication, occurs very often within 2 weeks of hemorrhagic stroke. DCI can cause brain injury and result in neurological defect and even death of aSAH patients (Budohoski et al., 2012; Duan et al., 2018) . Hence, its early identification might be beneficial for optimizing care and improving allocation of healthcare resources among aSAH patients.
WFNS scores, modified Fisher score, and Hunt-Hess score are highly associated with hemorrhagic severity after aSAH and are usually recorded to predict occurrence of DCI. However, DCI is a complex process with underlying complicated pathophysiological F I G U R E 2 Relationship between serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) levels and World Federation of Neurological Surgeons (WFNS) scores, modified Fisher scores, and Hunt-Hess scores in patients with aneurysmal subarachnoid hemorrhage mechanisms (Bacigaluppi et al., 2015; Carr et al., 2013; Foreman, 2016) . As a consequence, some biomarkers have been fully investigated for their predictive ability for DCI in recent decades (Yang et al., 2019; Zhu et al., 2019) .
LOX-1 emerged as a scavenger receptor present primarily on vascular endothelial cells. LOX-1 can combine with ox-LDL in endothelial cells and play a key role in vascular dysfunction, including apoptosis and inhibition of vasodilatation (Ma et al., (2006); Sakurai & Sawamura, 2003) . LOX-1 is also expressed in the intracerebral artery and its expression can be up-regulated significantly in rabbits with SAH (Matsuda et al., 2014) . In a previous case report, remarkable expressions of LOX-1 was found in hypertrophic media outside the intima in ruptured dissection using immunohistochemical examination (Saito, Fujimura, Inoue, Shimizu, & Tominaga, 2010) .
Moreover, among patients with acute intracerebral hemorrhage or acute ischemic stroke, circulating sLOX-1 levels were substantially raised, as compared to healthy controls (Inoue et al., 2019; Yokota et al., 2016) . Our clinical investigation showed that serum sLOX-1 levels were markedly raised after aSAH. Overall, LOX expression might be linked to human cerebral vascular dysfunction after aSAH.
Generally, WFNS scores, modified Fisher scores, and Hunt-Hess scores are widely used to assess hemorrhagic severity after aSAH.
Commonly, severe aSAH can be referred to as WFNS scores, modified Fisher scores, or Hunt-Hess scores ≥3 (Drake, 1988; Frontera et al., 2006; Mericle et al., 2006 ). In the current study, we confirmed that increasing circulating sLOX-1 levels were intimately correlated with rising disease severity indicated by the above-mentioned severity scales, namely, WFNS scores, modified Fisher scores, and Hunt-Hess scores. Meanwhile, patients with severe aSAH exhibited higher serum sLOX-1 levels, as compared to other remaining ones. Taken together, sLOX-1 in serum might be measured to assess hemorrhagic severity among aSAH patients.
In order to determine whether serum sLOX-1 was an independent predictor for occurrence of DCI, we at first used univariate analysis to discern the factors highly associated with occurrence of DCI. We Fisher scores retained as the independent predictors for development of DCI. Furthermore, in order to investigate the discriminatory capability for patients at risk of DCI, ROC curve was configured. We actually found that serum sLOX-1 levels were able to predict DCI significantly. Moreover, its predictive ability was similar to those of WNFS scores and modified Fisher scores. More intriguingly, serum sLOX-1 levels could be able to significantly improve the predictive capability of WFNS scores and modified Fisher score. In summary, serum sLOX-1 might serve as a potential biomarker for predicting occurrence of DCI after aSAH.
In this study, some considerations should be mentioned.
Laboratory test for serum sLOX-1 levels is convenient because residual blood from standard blood draws on admission can be used for its determination, and moreover most hospitals have already been equipped to perform such analysis. However, its daily measurement is a little difficult, and moreover, sLOX-1 expression might rise and fall over the 14-day DCI window, so its clinical use warrants to be considered cautiously. In future, it might be helpful to track the change of serum sLOX-1 levels over time.
| CON CLUS IONS
To the best of my knowledge, it is the first study for measuring serum sLOX-1 levels in a group of aSAH patients and further investigating its predictive ability for DCI. Of note, an elevation of serum 
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